Cross-resistance and molecular mechanisms in antiestrogen resistance

R. Clarke, N. Brünner

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Almost all initially responsive breast tumors acquire resistance to the triphenylethylene antiestrogen tamoxifen (TAM). Development of resistance represents the major restriction in the current use of TAM. More recently, a series of steroidal antiestrogens have been developed (e.g. ICI 182,780), and we wished to determine whether cross-resistance among these drugs occurs, and what the likely mechanisms of resistance are. We have further selected breast cancer variant cell lines that no longer require estrogens for growth (MCF-7/LCC-1) against either 4-hydroxytamoxifen (MCF-7/LLC-2) or ICI 182,780 (MCF-7/LCC-9). Analysis of the resistance phenotypes suggests that TAM resistant cells can retain responsiveness to the steroidal antiestrogens, whereas cells selected against ICI 182,780 are cross-resistant to TAM. If similar resistance patterns are acquired in patients, a sequential modality with TAN as the first-line and ICI 182,780 as a second-line drug, is suggested. We have generated a gene-network hypothesis to explain these differential resistance patterns and outline their potential molecular mechanisms.

Original languageEnglish (US)
Pages (from-to)59-72
Number of pages14
JournalEndocrine-related cancer
Volume2
Issue number1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint Dive into the research topics of 'Cross-resistance and molecular mechanisms in antiestrogen resistance'. Together they form a unique fingerprint.

Cite this